Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RVL-072
- Development stage
- Preclinical
- Lead developer
- Unravel Biosciences
- Modality
- Small Molecules
01
Overview
RVL-072 is a preclinical-stage small molecule developed by Unravel Biosciences for the treatment of ciliopathies. It was identified using Unravel's proprietary BioNAV platform, which utilizes AI-driven gene expression analysis and a Drosophila-to-human discovery engine to identify therapeutic candidates for rare diseases. Ciliopathies are a diverse group of genetic disorders caused by defects in the structure or function of cilia, hair-like organelles involved in cellular signaling and motility. As of 2024, the specific molecular target and mechanism of action for RVL-072 have not been publicly disclosed by the developer.
Beyond the preview
Go deeper on RVL-072.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RVL-072.